Почетна › Немалоклетни карцином плућа › Ilinois › Chicago
Kliničke studije za Немалоклетни карцином плућа u gradu Chicago, IL
59 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Chicago i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Тражи се учесникФаза 3
- University of Illinois Chicago, Chicago
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- University of Chicago, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Тражи се учесникФаза 2/3
- Rush University Medical Center, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Тражи се учесникФаза 3
- Northwestern University, Chicago
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Тражи се учесникФаза 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- и још 1
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Тражи се учесникФаза 3
- University of Illinois Cancer Center, Chicago
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Тражи се учесникФаза 3
- Local Institution - 0185, Chicago
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Тражи се учесникФаза 3
- Research Site, Chicago
- Research Site, Chicago
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Тражи се учесникФаза 3
- The University of Chicago Medical Center ( Site 0118), Chicago
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Тражи се учесникФаза 1/2
- University of Illinois Cancer Center, Chicago
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Illinois Cancer Specialists, Chicago
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Тражи се учесникФаза 3
- John H Stroger Jr Hospital of Cook County, Chicago
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Тражи се учесникФаза 3
- University of Chicago Medical Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- University of Chicago Hospital, Chicago
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- City of Hope, Chicago, Chicago
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Тражи се учесникФаза 1/2
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Тражи се учесникОпсервациона студија
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Тражи се учесникФаза 2
- Rush MD Anderson Cancer Center, Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Тражи се учесникФаза 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Тражи се учесникФаза 3
- Northwestern University, Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Тражи се учесникФаза 2/3
- University of Chicago, Chicago
Study of XB010 in Subjects With Solid Tumors
Тражи се учесникФаза 1
- University of Chicago Medical Center, Chicago
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Тражи се учесникФаза 1/2
- University of Chicago, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Research Site, Chicago
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Тражи се учесникФаза 3
- University of Chicago Medical Center ( Site 0145), Chicago
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Тражи се учесникФаза 3
- University of Illinois at Chicago, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Research Site, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Тражи се учесникФаза 1/2
- Northwestern Memorial Hospital, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Тражи се учесникФаза 3
- University of Illinois Medical Center, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #26, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Research Site, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- Northwestern University Feinberg School of Medicine, Chicago
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Тражи се учесникФаза 3
- Clinical Study Site, Chicago
- Clinical Study Site, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- University of Chicago, Chicago
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- Northwestern University, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Тражи се учесникФаза 3
- Northwestern University, Chicago
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Тражи се учесникФаза 3
- Northwestern University, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Тражи се учесникФаза 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Тражи се учесникФаза 1/2
- Northwestern Memorial Hospital, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Тражи се учесник
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Тражи се учесникФаза 1/2
- University of Chicago, Chicago
Segmentectomy After Induction Therapy (SAINT)
Тражи се учесник
- Northwestern University, Chicago
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Тражи се учесникФаза 2
- University of Illinois Cancer Center, Chicago
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Тражи се учесник
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Тражи се учесникФаза 1
- University of Chicago, Chicago
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Тражи се учесникОпсервациона студија
- University of Chicago, Chicago
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- Boston, MA87 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Columbus, OH57 студија
- Seattle, WA55 студија
- Washington, DC55 студија
Ostale studije u gradu Chicago
- Рак дојке59 студија
- Рак (све врсте)51 студија
- Рак простате45 студија
- Рак плућа43 студија
- Метастатски карцином42 студија
- Гојазност40 студија
- Рак јајника36 студија
- Колоректални карцином32 студија
- Шлог31 студија
- Плоскоклеточни карцином главе и врата29 студија
- Гојазност29 студија
- Затајење срца28 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.